Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis.

Leopardi M, Houbballah R, Becquemin JP.

J Cardiovasc Surg (Torino). 2014 Apr;55(2):229-34.

2.

Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.

Tran K, Ullery BW, Kret MR, Lee JT.

Ann Vasc Surg. 2017 Jan;38:90-98. doi: 10.1016/j.avsg.2016.08.006. Epub 2016 Aug 20.

PMID:
27554688
3.

Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.

Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, Ruhlmann C, Kavteladze Z, Lottes AE, Ragheb AO, Zeller T; Zilver PTX Single-Arm Study Investigators.

J Endovasc Ther. 2011 Oct;18(5):613-23. doi: 10.1583/11-3560.1.

PMID:
21992630
4.

Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.

Fujihara M, Utsunomiya M, Higashimori A, Yokoi Y, Nakamura M.

Heart Vessels. 2016 Feb;31(2):152-7. doi: 10.1007/s00380-014-0596-2. Epub 2014 Oct 29.

PMID:
25351136
5.

Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.

Zeller T, Dake MD, Tepe G, Brechtel K, Noory E, Beschorner U, Kultgen PL, Rastan A.

JACC Cardiovasc Interv. 2013 Mar;6(3):274-81. doi: 10.1016/j.jcin.2012.12.118.

6.

A single center experience of Zilver PTX for femoro-popliteal lesions.

Kang WY, Campia U, Didier RJ, Kiramijyan S, Koifman E, Negi SI, Lipinski MJ, Baker NC, Escarcega RO, Torguson R, Waksman R, Bernardo NL.

Cardiovasc Revasc Med. 2016 Sep;17(6):399-403. doi: 10.1016/j.carrev.2016.02.004. Epub 2016 Feb 9.

PMID:
27496591
7.

The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup.

Bosiers M, Peeters P, Tessarek J, Deloose K, Strickler S; Zilver PTX Single-Arm Study Investigators.

J Cardiovasc Surg (Torino). 2013 Feb;54(1):115-22.

8.

Comparison of SFA lesion treatment with Zilver PTX in diabetics vs. non-diabetics: 2-year clinical and functional results.

Oberto S, Cetta F, Trabattoni P, Zoli S, Tavano D, Rossi F, Clerici G, Airoldi F, Spirito R, Losa S.

J Cardiovasc Surg (Torino). 2017 Aug;58(4):565-573. doi: 10.23736/S0021-9509.16.08563-3. Epub 2015 Mar 20.

9.

Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.

Wooster M, Dansey K, Shames M.

Vasc Endovascular Surg. 2016 Feb;50(2):80-3. doi: 10.1177/1538574416628651. Epub 2016 Feb 11.

PMID:
26912397
10.

Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.

Gouëffic Y, Kaladji A, Guyomarch B, Montagne C, Fairier D, Gestin S, Riche VP, Vent PA, Chaillou P, Costargent A, Patra P.

Trials. 2014 Oct 30;15:423. doi: 10.1186/1745-6215-15-423.

11.

1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.

Iida O, Takahara M, Soga Y, Nakano M, Yamauchi Y, Zen K, Kawasaki D, Nanto S, Yokoi H, Uematsu M; ZEPHYR Investigators.

JACC Cardiovasc Interv. 2015 Jul;8(8):1105-1112. doi: 10.1016/j.jcin.2015.03.022. Epub 2015 Jun 24.

12.

Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).

Liistro F, Grotti S, Porto I, Angioli P, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G, Bolognese L.

JACC Cardiovasc Interv. 2013 Dec;6(12):1295-302. doi: 10.1016/j.jcin.2013.07.010. Epub 2013 Nov 13.

13.

Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.

Ohki T, Yokoi H, Kichikawa K, Kimura T, Snyder SA, Ragheb AO, O'Leary EE, Jaff MR, Ansel GM, Dake MD.

J Endovasc Ther. 2014 Oct;21(5):644-53. doi: 10.1583/14-4753.1.

PMID:
25290792
14.

Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.

Zen K, Takahara M, Iida O, Soga Y, Kawasaki D, Nanto S, Yokoi H, Matoba S; ZEPHYR Investigators.

J Vasc Surg. 2017 Mar;65(3):720-725. doi: 10.1016/j.jvs.2016.10.098. Epub 2017 Jan 7.

PMID:
28073668
15.

Propensity Score Analysis Comparing Clinical Outcomes of Drug-Eluting vs Bare Nitinol Stents in Femoropopliteal Lesions.

Soga Y, Takahara M, Iida O, Nakano M, Yamauchi Y, Zen K, Kawasaki D, Ando K.

J Endovasc Ther. 2016 Feb;23(1):33-9. doi: 10.1177/1526602815622953.

PMID:
26763256
16.

Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.

Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E.

J Endovasc Ther. 2014 Jun;21(3):359-68. doi: 10.1583/13-4630MR.1.

PMID:
24915582
17.

Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.

Grotti S, Liistro F, Angioli P, Ducci K, Falsini G, Porto I, Ricci L, Ventoruzzo G, Turini F, Bellandi G, Bolognese L.

J Endovasc Ther. 2016 Feb;23(1):52-7. doi: 10.1177/1526602815614555. Epub 2015 Oct 28.

PMID:
26511896
18.

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.

Chan YC, Cheng SW, Cheung GC.

J Vasc Surg. 2015 Nov;62(5):1201-9. doi: 10.1016/j.jvs.2015.05.030. Epub 2015 Jul 11.

19.

Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.

Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Suematsu N, Yamaoka T, Nanto S, Uematsu M.

J Endovasc Ther. 2014 Aug;21(4):485-92. doi: 10.1583/14-4721R.1.

PMID:
25101575
20.

Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.

Miki K, Fujii K, Kawasaki D, Shibuya M, Fukunaga M, Imanaka T, Tamaru H, Sumiyoshi A, Nishimura M, Horimatsu T, Saita T, Okada K, Kimura T, Honda Y, Fitzgerald PJ, Masuyama T, Ishihara M.

J Endovasc Ther. 2016 Jun;23(3):424-32. doi: 10.1177/1526602816641669. Epub 2016 Apr 4.

PMID:
27044270

Supplemental Content

Support Center